Related references
Note: Only part of the references are listed.A phase I/II study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer: Safety report.
Maria Pia Morelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Oncolytic viruses: how lytic must they be for therapeutic efficacy?
Maria Eugenia Davola et al.
ONCOIMMUNOLOGY (2019)
Bibliometric analysis of oncolytic virus research, 2000 to 2018
Yidi Zou et al.
MEDICINE (2019)
A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma
So Young Yoo et al.
CANCERS (2019)
Local delivery of a cancer-favoring oncolytic vaccinia virus via poly (lactic-co-glycolic acid) nanofiber for theranostic purposes
Narayanasamy Badrinath et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Trends in the global immuno-oncology landscape
Jun Tang et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi-Boateng et al.
NATURE REVIEWS CANCER (2018)
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
So Young Yoo et al.
MEDIATORS OF INFLAMMATION (2017)
Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma
So Young Yoo et al.
ONCOTARGET (2017)
Normalizing tumoral vessels to treat cancer: an out-of-the-box strategy involving TIE2 pathway
Juan Fueyo et al.
TRANSLATIONAL CANCER RESEARCH (2017)
Oncolytic Viruses in Cancer Treatment A Review
Sean E. Lawler et al.
JAMA ONCOLOGY (2017)
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment
Jin-Sung Park et al.
CANCER CELL (2016)
Viruses as nanomedicine for cancer
Narayanasamy Badrinath et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)
A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer
So Young Yoo et al.
ONCOTARGET (2016)
Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy
Galina Kochneva et al.
ONCOTARGET (2016)
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
Hasan Rehman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Replicating poxviruses for human cancer therapy
Manbok Kim
JOURNAL OF MICROBIOLOGY (2015)
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
Se Hoon Park et al.
MOLECULAR THERAPY (2015)
First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity
Herbert J. Zeh et al.
MOLECULAR THERAPY (2015)
Virotherapy - cancer targeted pharmacology
Alison Tedcastle et al.
DRUG DISCOVERY TODAY (2012)
Oncolytic vaccinia virus for the treatment of cancer
Kilian Guse et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Antiangiogenic Arming of an Oncolytic Vaccinia Virus Enhances Antitumor Efficacy in Renal Cell Cancer Models
Kilian Guse et al.
JOURNAL OF VIROLOGY (2010)
Progressive divergence of definitive haematopoietic stem cells from the endothelial compartment does not depend on contact with the foetal liver
S Taoudi et al.
DEVELOPMENT (2005)
The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program
GA Poland et al.
VACCINE (2005)
Overview of cell death signaling pathways
ZY Jin et al.
CANCER BIOLOGY & THERAPY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1)
C Daly et al.
GENES & DEVELOPMENT (2004)
The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Paladebodies
U Fiedler et al.
BLOOD (2004)
Molecular regulation of vessel maturation
RK Jain
NATURE MEDICINE (2003)
Angiogenesis in health and disease
P Carmeliet
NATURE MEDICINE (2003)
Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant
M Puhlmann et al.
CANCER GENE THERAPY (2000)
Share Paper
